Home > Cardiology > ISTH 2020 > Pearls of the Posters > Similar bleeding rates in patients with VTE and AF treated with DOACs

Similar bleeding rates in patients with VTE and AF treated with DOACs

Presented By
Dr Farès Moustafa, CHU Clermont Ferrand, France
Conference
ISTH 2020
  A retrospective study from a French emergency department including 525 patients with venous thromboembolic disease (VTE) and atrial fibrillation (AF) found no difference in bleeding risk during therapy with direct oral anticoagulants (DOACs) for these medical conditions [1]. The use of DOACs is an integral part in the management of different indications such as AF and VTE; and, as with any anticoagulation treatment, their use may be associated with the occurrence of haemorrhagic complications. Using information from a database in an emergency department, a retrospective study assessed the incidence of haemorrhage in patients with VTE or AF, The majority of the 525 included patients were treated with a DOAC (i.e. dabigatran, rivaroxaban, or apixaban) for AF (71.6%), another 149 (28.4%) were treated for VTE. Patients with both VTE and AF were excluded. In total, 95 patients were admitted due to haemorrhage: 27 VTE patients (28.4%...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on